Imipenem/Cilastatin/Relebactam ( DrugBank: Cilastatin, Imipenem, Relebactam )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症1

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05561764
(ClinicalTrials.gov)
January 3, 202327/9/2022Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic FibrosisA Multicenter, Open-label Study to Determine the Pharmacokinetics, Safety, and Outcomes of Imipenem/Cilastatin/Relebactam During Treatment of Acute Pulmonary Exacerbations in Adolescent and Adult Patients With Cystic FibrosisCystic Fibrosis;Pneumonia, BacterialDrug: Imipenem/Cilastatin/RelebactamHartford HospitalMerck Sharp & Dohme LLC;Q2 Solutions;Connecticut Children's Medical Center;St. Christopher's Hospital for Children;University of Texas Southwestern Medical Center;University of Pittsburgh Medical Center;Indiana University Health Methodist Hospital;James Whitcomb Riley Hospital for ChildrenRecruiting12 YearsN/AAll16Phase 4United States